Dieter Glebe

Kontakt

        +49 6491 99 412

       E-mail

       Schubertstrasse 81

       35392 Giessen

Position

• group leader

The scientific focus of my academic career can be divided into three main areas of interest.

(A) Genotypic and phenotypic characterisation of novel animal HBV/HDV-viruses.

Here, I characterized novel animal HBV/HDV by cloning and expression and subsequent infection in vitro using own established infection systems for HBV/HDV and pseudotyped HDV (see below).

1. Paraskevopoulou S, et al. & Sommer S*, Glebe D*, Drosten C*. 2020. Mammalian deltavirus without hepadnavirus coinfection in the neotropical rodent Proechimys semispinosus. Proc. Natl. Acad. Sci. USA. 117:17977-17983. doi: 10.1073/pnas.2006750117 (*shared senior authors).
2. Rasche A, et al. & Glebe D*, Drexler JF*. 2019. Highly diversified shrew hepatitis B viruses corroborate ancient origins and divergent infection patterns of mammalian hepadnaviruses. Proc. Natl. Acad. Sci. USA. 116:17007-17012. doi: 10.1073/pnas.1908072116 (*shared senior authors).
3. de Carvalho Dominguez Souza BF et al. & Glebe D*, Felix Drexler JF*. 2018. A novel hepatitis B virus species discovered in capuchin monkeys sheds new light on the evolution of primate hepadnaviruses. J Hepatol. 68:1114-1122. doi: 10.1016/j.jhep.2018.01.029 (*shared senior authors).

(B) Establishment and improvement of HBV/HDV-infection systems in vitro

Since 2003, I have been developing and optimising systems for both in vitro generation of human/animal HBV/HDV and corresponding infection systems using primary hepatocytes and susceptible permanent cell cultures.

4. König A, et al. & Glebe D. 2014 Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes. J Hepatol. 61: 867-875. doi: 10.1016/j.jhep.2014.05.018.
5. Bremer CM et al. & Glebe D. 2011. N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus. J Hepatol. 55:29-37. doi: 10.1016/j.jhep.2010.10.019.
6. Glebe D et al. 2005. Mapping of hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and Tupaia hepatocytes. Gastroenterology 129: 234-245. doi: 10.1053/j.gastro.2005.03.090

(C) Improved molecular diagnostics and characterization of HBV and HDV infection

The phenotypic characterization of a large number of clinical HBV/HDV isolates and the genotypic analysis of ancient HBV isolates were successfully completed as part of the activities of the National Reference Centre for HBV/HDV in Giessen, which I have been heading since 2011.

7. Lehmann F et al. & Glebe D. 2023. A Novel Insertion in the Hepatitis B Virus Surface Protein Leading to Hyperglycosylation Causes Diagnostic and Immune Escape. Viruses. 15(4):838. doi: 10.3390/v15040838.
8. Giersch K, Perez-Gonzalez P, Hendricks L, Goldmann N, Kolbe J, Hermanussen L, Bockmann JH, Volz T, Volmari A, Allweiss L, Petersen J, Glebe D, Lütgehetmann M, Dandri M. 2023. Strain-specific responsiveness of hepatitis D virus to interferon-alpha treatment. JHEP Rep. 2023 Jan 24;5(4):100673. doi: 10.1016/j.jhepr.2023.100673.
9. Pfefferkorn M, Schott T, Böhm S, Deichsel D, Felkel C, Gerlich WH, Glebe D, Wat C, Pavlovic V, Heyne R, Berg T, van Bömmel F. 2021. Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B. J Hepatol. Feb;74(2):283-292. doi: 10.1016/j.jhep.2020.08.039.
10. Mühlemann B, Jones TC, Damgaard PB, Allentoft ME, Shevnina I, Logvin A, Usmanova E, Panyushkina IP, Boldgiv B, Bazartseren T, Tashbaeva K, Merz V, Lau N, Smrčka V, Voyakin D, Kitov E, Epimakhov A, Pokutta D, Vicze M, Price TD, Moiseyev V, Hansen AJ, Orlando L, Rasmussen S, Sikora M, Vinner L, Osterhaus ADME, Smith DJ, Glebe D, Fouchier RAM, Drosten C, Sjögren KG, Kristiansen K, Willerslev E. 2018. Ancient hepatitis B viruses from the Bronze Age to the Medieval period. Nature 557:418-423. doi: 10.1038/s41586-018-0097-z